Atossa Therapeutics, Inc.

NasdaqCM:ATOS 주식 보고서

시가총액: US$189.9m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Atossa Therapeutics 관리

관리 기준 확인 3/4

Atossa Therapeutics' CEO는 Steve Quay, Apr2009 에 임명되었습니다 의 임기는 15.33 년입니다. 총 연간 보상은 $ 2.36M, 30% 로 구성됩니다. 30% 급여 및 70% 보너스(회사 주식 및 옵션 포함). 는 $ 3.56K 가치에 해당하는 회사 주식의 0.002% 직접 소유합니다. 3.56K. 경영진과 이사회의 평균 재임 기간은 각각 3.6 년과 12.5 년입니다.

주요 정보

Steve Quay

최고 경영자

US$2.4m

총 보상

CEO 급여 비율30.0%
CEO 임기15.4yrs
CEO 소유권0.002%
경영진 평균 재임 기간3.7yrs
이사회 평균 재임 기간12.6yrs

최근 관리 업데이트

Recent updates

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Jul 01
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Mar 07
Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Nov 08
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

Apr 26
Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Jan 09
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Atossa Therapeutics: Still Gets An 'Incomplete' Rating

Oct 11

We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely

Sep 25
We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely

Atossa Therapeutics GAAP EPS of -$0.05

Aug 08

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

May 12
Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

A First Assessment On Atossa Therapeutics

Dec 10

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Dec 02
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World

Sep 22

Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business

Jul 17
Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business

Atossa Therapeutics: Hope Springs Eternal

Jun 30

Atossa Therapeutics to be included in the Russell 2000, 3000 indexes

Jun 16

Atossa reaches a two-year high ahead of data readout for breast cancer therapy

Jun 07

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Apr 02
Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Atossa updates on single-patient study for Endoxifen

Feb 04

Atossa halts Endoxifen breast cancer study after positive data

Feb 02

Atossa Therapeutics prices ~$25M direct offering, stock -23% PM

Jan 06

Atossa Therapeutics prices $14M registered direct offering

Dec 17

We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Dec 10
We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Atossa Therapeutics plummets 38% after it raises $20M in public offering

Dec 09

Atossa Therapeutics EPS in-line

Nov 13

Safety data on COVID-19 nasal spray fails to lift Atossa, down 6%

Nov 10

CEO 보상 분석

Steve Quay 의 보수는 Atossa Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$26m

Mar 31 2024n/an/a

-US$30m

Dec 31 2023US$2mUS$706k

-US$30m

Sep 30 2023n/an/a

-US$30m

Jun 30 2023n/an/a

-US$32m

Mar 31 2023n/an/a

-US$28m

Dec 31 2022US$3mUS$706k

-US$27m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$21m

Mar 31 2022n/an/a

-US$22m

Dec 31 2021US$6mUS$659k

-US$21m

Sep 30 2021n/an/a

-US$28m

Jun 30 2021n/an/a

-US$26m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$3mUS$601k

-US$22m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020n/an/a

-US$13m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$6mUS$601k

-US$17m

Sep 30 2019n/an/a

-US$17m

Jun 30 2019n/an/a

-US$17m

Mar 31 2019n/an/a

-US$25m

Dec 31 2018US$2mUS$582k

-US$23m

Sep 30 2018n/an/a

-US$23m

Jun 30 2018n/an/a

-US$22m

Mar 31 2018n/an/a

-US$11m

Dec 31 2017US$1mUS$520k

-US$11m

보상 대 시장: Steve 의 총 보상 ($USD 2.36M )은 US 시장( $USD 1.52M ).

보상과 수익: Steve 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Steve Quay (73 yo)

15.4yrs

테뉴어

US$2,356,220

보상

Dr. Steven C. Quay, also known as Steve, M.D., Ph D., FCAP, has been the Chief Executive Officer and President of Atossa Therapeutics, Inc. (formerly known as Atossa Genetics Inc.) since April 30, 2009 and...

리더십 팀

이름위치테뉴어보상소유권
Steven Quay
Chairman15.4yrsUS$2.36m0.0021%
$ 4.0k
Heather Rees
Chief Financial Officer & Principal Accounting Officer3.7yrsUS$687.46k0%
$ 0
Delly Behen
Senior Vice President of Administration & HR10.2yrs데이터 없음데이터 없음
Eric Van Zanten
Vice President of Investor & Public Relations2.7yrs데이터 없음데이터 없음
Richard Graydon
Interim Chief Medical Officer1.9yrs데이터 없음데이터 없음

3.7yrs

평균 재임 기간

경험이 풍부한 관리: ATOS 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Steven Quay
Chairman15.4yrsUS$2.36m0.0021%
$ 4.0k
Richard Steinhart
Independent Director10.5yrsUS$146.17k0%
$ 0
H. Remmel
Independent Director12.6yrsUS$144.92k0.00020%
$ 379.8
Shu-Chih Chen
Director15.4yrsUS$116.17k0.018%
$ 33.6k
Stephen Galli
Independent Director13.2yrsUS$144.92k0.000080%
$ 151.9
Jonathan Finn
Independent Directorless than a yearUS$93.98k0.020%
$ 37.8k
Tessa Cigler
Independent Directorless than a year데이터 없음데이터 없음

12.6yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: ATOS 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 12.5 년).